Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 4/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.46 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | DRD1 | P21728 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | CCR2 | P41597 | 1/20 | 0.46 |
| ▸ | DHODH | Q02127 | 1/20 | 0.45 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL343533 | 0.82 | NR4A1 (0.50) | ALDH1A1HPGDCYP1A2CYP3A4TDP1 | |
| SCHEMBL79801 | 0.80 | SIGMAR1 (0.49) | ALDH1A1HPGDCYP1A2CYP3A4TDP1 | |
| SCHEMBL4172132 | 0.79 | SIGMAR1 (0.43) | ALDH1A1HPGDCYP1A2CYP3A4TDP1 | |
| SCHEMBL283065 | 0.79 | ALDH1A1 (0.44) | ALDH1A1HPGDCYP1A2CYP3A4TDP1 | |
| SCHEMBL7445149 | 0.78 | SIGMAR1 (0.42) | ALDH1A1HPGDCYP1A2CYP3A4TDP1 | |
| SCHEMBL7089296 | 0.77 | CYP1A2 (0.50) | ALDH1A1HPGDCYP1A2CYP3A4TDP1 | |
| SCHEMBL7089301 | 0.77 | CYP1A2 (0.50) | ALDH1A1HPGDCYP1A2CYP3A4TDP1 | |
| SCHEMBL7443122 | 0.77 | DHODH (0.43) | ALDH1A1HPGDCYP1A2CYP3A4TDP1 | |
| SCHEMBL7443116 | 0.77 | DHODH (0.43) | ALDH1A1HPGDCYP1A2CYP3A4TDP1 | |
| SCHEMBL7449481 | 0.76 | DHODH (0.45) | ALDH1A1HPGDCYP1A2CYP3A4TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009023669-A1 | SUBSTITUTED 5,6,7,8-TETRAHYDROQUINOLINE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE THEREOF | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-02-19 | — | — | WO | claimed |
| US-20090048295-A1 | SUBSTITUTED 5,6,7,8-TETRAHYDROQUINOLINE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE THEREOF | JANSSEN PHARMACEUTICE N.V. (BE) | 2009-02-19 | — | — | US | claimed |
| US-8497397-B2 | Substituted acrylamide derivative and pharmaceutical composition comprising the same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-07-30 | — | — | US | disclosed |
| EP-1880720-B1 | SUBSTITUTED ACRYLAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAIICHI SANKYO CO LTD (JP) | 2013-02-13 | — | — | EP | disclosed |
| US-8344029-B2 | Substituted propanamide derivative and pharmaceutical composition containing the same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-01-01 | — | — | US | disclosed |
| US-20120220593-A1 | Substituted Acrylamide Derivative and Pharmaceutical Composition Comprising the Same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-08-30 | — | — | US | disclosed |
| US-8143446-B2 | Substituted acrylamide derivative and pharmaceutical composition comprising the same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-27 | — | — | US | disclosed |
| US-20090292024-A1 | SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-11-26 | — | — | US | disclosed |
| US-20090118199-A1 | SUBSTITUTED ACRYLAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAIICHI SANKYO COMPANY , LIMITED (JP) | 2009-05-07 | — | — | US | disclosed |
| WO-2009023669-A1 | SUBSTITUTED 5,6,7,8-TETRAHYDROQUINOLINE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE THEREOF | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-02-19 | — | — | WO | disclosed |
| US-20090048295-A1 | SUBSTITUTED 5,6,7,8-TETRAHYDROQUINOLINE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE THEREOF | JANSSEN PHARMACEUTICE N.V. (BE) | 2009-02-19 | — | — | US | disclosed |
| EP-1908466-A1 | SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Daiichi Sankyo Company, Limited (JP) | 2008-04-09 | — | — | EP | disclosed |
| EP-1880720-A1 | SUBSTITUTED ACRYLAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Daiichi Sankyo Company, Limited (JP) | 2008-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090292024-A1 | SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | PTMS, C1S, ACP3 | ALDH1A1 298/4885HPGD 985/4885CYP1A2 1134/4885 |
| US-20090048295-A1 | SUBSTITUTED 5,6,7,8-TETRAHYDROQUINOLINE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE THEREOF | C3AR1, C5AR1, C5AR2 | ALDH1A1 3130/4885HPGD 406/4885CYP1A2 1229/4885 |
| US-20090118199-A1 | SUBSTITUTED ACRYLAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | ACR, NAT1, C1S | ALDH1A1 75/4885HPGD 570/4885CYP1A2 40/4885 |
| US-20120220593-A1 | Substituted Acrylamide Derivative and Pharmaceutical Composition Comprising the Same | ACR, NAT1, C1S | ALDH1A1 75/4885HPGD 570/4885CYP1A2 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.